This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Tap the Red Hot Biotech Sector With These 2 Leveraged ETFs
by Sweta Killa
Investors could easily tap the bullish trend by considering a near-term long on the biotech sector.
J&J (JNJ) Reports Positive Interim Data on COVID Booster Jab
by Zacks Equity Research
The booster dose of J&J's (JNJ) single-shot COVID-19 vaccine achieves rapid and robust increase in spike-binding antibodies in previously vaccinated people with the initial dose.
Moderna (MRNA) Seeks Full FDA Approval for COVID-19 Vaccine
by Zacks Equity Research
Moderna (MRNA) completes rolling submission of BLA to the FDA seeking full approval of its COVID-19 vaccine candidate, mRNA-1273, in the United States.
5 Tech ETFs Outperforming the Market This Year
by Sweta Killa
The technology sector has regained strong momentum lately, making it one of the outperforming sectors of this year.
ETFs to Rise on Full FDA Approval for Pfizer COVID-19 Vaccine
by Sweta Jaiswal, FRM
Let's look at the ETFs that are well-poised to gain as Comirnaty's full FDA approval is likely to drive the vaccination rate.
Will CARZ ETF Gain Despite Mixed Auto Earnings?
by Sweta Jaiswal, FRM
Let's take a look at the impact of major automakers' earnings releases on automobile ETF amid the coronavirus crisis.
Nasdaq Tops 15K for First Time: 5 Best Stocks in the ETF
by Sweta Killa
The tech-heavy Nasdaq Composite Index topped 15,000 for the first time ever driven by continued strength in tech stocks.
High-Beta ETFs to Bet on Renewed Market Momentum
by Sweta Killa
High-beta ETFs seek to capitalize on consistent growth with market-beating returns.
AbbVie's (ABBV) Rinvoq Gets Approval for Eczema in Europe
by Zacks Equity Research
AbbVie's (ABBV) European approval for Rinvoq for atopic dermatitis marks the fourth EC-approved indication for the JAK inhibitor drug.
Stock Market News for Aug 25, 2021
by Zacks Equity Research
U.S. stocks continued their winning-run on Tuesday supported by the FDA¿¿¿s first full approval of COVID-19 vaccines.
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, BioNTech, Moderna, Johnson & Johnson and Novavax
6 Must-Buy Corporate Giants As Major Indexes Hit Record High
by Nalak Das
We have narrowed down our search to six stocks that are members of any of the three major indexes. These are: MRNA, NVDA, TJX, AAPL, DE and REGN.
3 Big Drug/Biotech Outperformers Worth Keeping an Eye On (Revised)
by Kinjel Shah
Eli Lilly (LLY), Pfizer (PFE) and Novo Nordisk (NVO) are three large drugmakers that have outperformed the industry and are good stocks to hold for the next few months and beyond.
Nasdaq Crosses 15K for 1st Time Ever; JWN, URBN Beat
by Mark Vickery
On the way to its fourth-straight up day in the market, the tech-heavy Nasdaq wound up surpassing 15K for its first time ever.
Pfizer Vaccine Approval Triggers a Surge in Biotech ETFs
by Sweta Jaiswal, FRM
The biotech space has once again come under the spotlight as the FDA has granted the first full U.S. approval to Pfizer (PFE)/BioNTech's (BNTX) coronavirus vaccine.
Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion
by Zacks Equity Research
Trillium (TRIL) is set to be acquired by Pfizer for $2.3 billion or $18.50 per share. Stock shoots up.
Dynavax (DVAX) Gains as Medigen Rolls Out COVID-19 Vaccine
by Zacks Equity Research
Dynavax (DVAX) stock gains as partner Medigen announces launch of its COVID-19 vaccine MVC-COV1901 adjuvanted with CpG 1018 of the former.
Healthcare ETFs Surge on FDA Full-Vaccine Nod & Deal News
by Sweta Killa
The FDA granted full approval of a COVID-19 vaccine made by Pfizer (PFE) and BioNTech that could accelerate inoculations in the United States.
FDA Grants First Full Approval of COVID-19 Vaccine
by Zacks Equity Research
FDA Grants First Full Approval of COVID-19 Vaccine.
Indexes Back At (or Near) All-Time Highs; BBY Beats Estimates
by Mark Vickery
The Nasdaq has registered its first all-time closing high for the first time since August 5th.
Stock Market News for Aug 24, 2021
by Zacks Equity Research
U.S. stock markets rallied on Monday after a disappointing last week.
3 COVID Vaccine Makers to Watch on Pfizer Jab Full FDA Approval
by Zacks Equity Research
Stocks of coronavirus vaccine makers BNTX and MRNA fly high following complete approval of Pfizer's COVID-19 vaccine. The momentum is likely to continue for these stocks. JNJ is another strong contender in this field.
Company News for Aug 24, 2021
by Zacks Equity Research
Companies In The News Are: GM, JD, PFE, TRIL, MSGE.
Pfizer (PFE)/BioNTech Comirnaty Gets FDA's Full Approval
by Zacks Equity Research
Pfizer (PFE)/BioNTech's (BNTX) mRNA-based COVID-19 vaccine, Comirnaty becomes the first vaccine to be granted full approval by the FDA.
5 Stocks At the Forefront of the Latest S&P 500 Rally
by Sweta Killa
The S&P 500 showed strength to start the new week and hit a new peak on a vaccine boost. This benefited the KR, REGN, TJX, ISRG, MSFT stocks.